Latest News

US researchers find vitamin B3 prevents glaucoma

US researchers find vitamin B3 prevents glaucoma

Novartis and NHS Ayrshire & Arran launch new eye care facility in Scotland

Novartis Pharmaceuticals UK and NHS Ayrshire & Arran have announced the launch of a new facility designed specifically for people suffering from some of the most common forms of avoidable sight loss....

Novartis and NHS Ayrshire & Arran launch new eye care facility in Scotland

Is digital disruption of heart disease markets on the horizon?

Is digital disruption of heart disease markets on the horizon?

Cutting costs but not quality: heart failure hospitalisations

Cutting costs but not quality: heart failure hospitalisations

US FDA approves Siliq to treat plaque psoriasis

US FDA approves Siliq to treat plaque psoriasis

Eli Lilly and Incyte receive EC’s marketing authorisation approval for Olumiant

Eli Lilly and Incyte receive EC’s marketing authorisation approval for Olumiant

Vifor Pharma gains commercialisation rights for ChemoCentryx’s Avacopan in Asia

Swiss-based Vifor Pharma, a Galenica Group company, has gained commercialisation rights for ChemoCentryx’s Avacopan (CCX168) for orphan and rare renal diseases in Asia, including Japan and...

Vifor Pharma gains commercialisation rights for ChemoCentryx’s Avacopan in Asia

Bristol-Myers Squibb and pCPA sign agreement for OPDIVO treatment

Bristol-Myers Squibb Canada (BMS) and the pan-Canadian Pharmaceutical Alliance (pCPA) have signed an agreement for immuno-oncology treatment OPDIVO. ...

Bristol-Myers Squibb and pCPA sign agreement for OPDIVO treatment

US FDA approves Emflaza tablets to treat patients with DMD

US FDA approves Emflaza tablets to treat patients with DMD

AstraZeneca awards grants for new programmes to improve heart health

US-based AstraZeneca HealthCare Foundation has awarded grants to ten community-based programmes that will work to improve the heart health of local...

AstraZeneca awards grants for new programmes to improve heart health

US FDA approves Amgen’s Parsabiv to treat HPT in adult patients

The US Food and Drug Administration (FDA) has approved Amgen’s Parsabiv (etelcalcetide) to treat secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD)...

US FDA approves Amgen’s Parsabiv to treat HPT in adult patients

Prexton to fund two Phase II studies of Foliglurax in Parkinson’s disease

Prexton to fund two Phase II studies of Foliglurax in Parkinson’s disease

Study links immune system genetic variants to development of leukaemia

Study links immune system genetic variants to development of leukaemia

FDA approves Bristol-Myers Squibb’s Opdivo injection to treat mUC

The US Food and Drug Administration (FDA) has approved Bristol-Myers Squibb’s Opdivo injection (nivolumab) for intravenous use in previously treated, locally advanced or metastatic...

FDA approves Bristol-Myers Squibb’s Opdivo injection to treat mUC

UK MHRA recommends Roche’s new immunotherapy atezolizumab for bladder cancer

UK MHRA recommends Roche’s new immunotherapy atezolizumab for bladder cancer

AstraZeneca announces availability of saxa / dapa FDC in UK

UK-based AstraZeneca has announced the availability of Qtern (saxagliptin and dapagliflozin fixed-dose combination) for adult patients with type 2 diabetes....

AstraZeneca announces availability of saxa / dapa FDC in UK

US FDA accepts Genentech Actemra’s sBLA for Giant Cell Arteritis

US FDA accepts Genentech Actemra’s sBLA for Giant Cell Arteritis

New research reveals caspase-2 enzyme deficiency increases risk of developing tumours

Researchers from the University of South Australia at the Centre for Cancer Biology have revealed that people with a deficiency of enzyme caspase-2 are at a higher risk of developing...

New research reveals caspase-2 enzyme deficiency increases risk of developing tumours

Merck agrees to resolve Keytruda patent infringement litigation

Merck agrees to resolve Keytruda patent infringement litigation

Malecare launches new mobile application Cancergraph to track cancer symptoms

US-based men’s cancer survivor support and advocacy national non-profit organisation Malecare has launched a new mobile application, Cancergraph, which tracks cancer...

Malecare launches new mobile application Cancergraph to track cancer symptoms

Eisai acquires manufacturing rights for API from Roche to treat insomnia

Eisai has acquired the rights for manufacturing active pharmaceutical ingredients (API) for Japan from F Hoffman-La Roche for the insomnia treatment / anaesthesia induction agent...

Eisai acquires manufacturing rights for API from Roche to treat insomnia
cachename:Newscachekey:rd-137342983_-144940029_rd-1665407042_1857678299_rd-488908060_1460672566_ap1460672566_1857678299_651428199